2021 Insights into Keratitis (Ophthalmology) Drugs In Development – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Keratitis (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Keratitis (Ophthalmology) pipeline landscape. Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

This report provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The report also reviews key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 4, 3, 1, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

It helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

   

Key Topics Covered:

• Introduction
• Overview
• Therapeutics Development
• Therapeutics Assessment
• Companies Involved in Therapeutics Development
• Drug Profiles
• Dormant Projects
• Discontinued Products
• Appendix

Companies Mentioned

• Alfasigma SpA
• AmebaGone Inc
• Claris Biotherapeutics Inc
• Cumulus Pharmaceutical LLC
• Dobecure SL
• Editas Medicine Inc
• EyeGate Pharmaceuticals Inc
• Fox Chase Chemical Diversity Center Inc
• iVeena Delivery Systems Inc
• Knight Therapeutics Inc
• MimeTech Srl
• NanoViricides Inc
• Neuroptika Inc
• Oyster Point Pharma Inc
• Provectus Biopharmaceuticals Inc
• RegeneRx Biopharmaceuticals Inc
• Riptide Bioscience Inc
• Shanghai Bendao Gene Technology Co Ltd
• Shenyang Sinqi Pharmaceutical Co Ltd
• Shulov Innovative Science Ltd
• Sinsa Labs Inc
• TGV-Inhalonix Inc
• Veloce BioPharma LLC
• Viraze
• Zylem Biosciences Inc

For more information about this report visit https://www.researchandmarkets.com/r/n7e48u

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900